Results 181 to 190 of about 12,554 (221)
Some of the next articles are maybe not open access.
The Efficacy of Acellular Pertussis Vaccine
JAMA: The Journal of the American Medical Association, 1989To the Editor.— Reporting from a workshop at the National Institutes of Health, Bethesda, Md, 1 Mr Marwick stated that "the large Swedish field trial of two acellular pertussis vaccines 2 has not shown levels of efficacy high enough to make either vaccine a likely candidatefor immediate licensure in the United States." We can now report efficacy data ...
P, Olin, J, Storsaeter, V, Romanus
openaire +2 more sources
Protective effect of acellular pertussis vaccines
European Journal of Clinical Microbiology & Infectious Diseases, 1988Two acellular pertussis vaccines, a mono-component toxoid of pertussis toxin and a two-component vaccine containing both the toxoid and filamentous haemagglutinin, were used for primary immunization of infants 5 1/2 to 10 months of age in two clinical trials in Sweden. Over a follow-up period of 12 to 17 months, 37 children were exposed to pertussis in
M, Blennow, S, Hedenskog, M, Granström
openaire +2 more sources
American Journal of Diseases of Children, 1991
The efficacy of two acellular pertussis vaccines was estimated for various clinical case definitions, with and without the requirement of culture confirmation, from a randomized trial in Sweden. Efficacy increased with duration of coughing spasms and when the case definition included whoops or whoops plus at least nine coughing spasms a day.
W C, Blackwelder +3 more
openaire +2 more sources
The efficacy of two acellular pertussis vaccines was estimated for various clinical case definitions, with and without the requirement of culture confirmation, from a randomized trial in Sweden. Efficacy increased with duration of coughing spasms and when the case definition included whoops or whoops plus at least nine coughing spasms a day.
W C, Blackwelder +3 more
openaire +2 more sources
Pertussis vaccines: acellular versus whole‐cell
Medical Journal of Australia, 1996Acellular pertussis vaccines containing purified Bordetella pertussis antigens have now been extensively field tested. They produce a significantly lower rate of reactions than whole-cell vaccines and their efficacy is either comparable or superior.
openaire +2 more sources
Acellular Vaccines and Resurgence of Pertussis
JAMA, 2012PERTUSSIS IS A HIGHLY CONTAGIOUS, VACCINEpreventable disease for which a whole-cell vaccine (killed bacteria), in combination with toxoids against diphtheria and tetanus (DTwP), was introduced for immunization of children in the United States in the 1940s. With the eventual widespread use of DTwP vaccine, the national annual incidence of reported cases
openaire +2 more sources
2016
Pertussis is a dangerous infectious disease that is well controlled world-wide by widespread immunization. The major cause of the decline in the morbidity and mortality of the disease is the intensive World Health Organization's Expanded Program on Immunization.
openaire +1 more source
Pertussis is a dangerous infectious disease that is well controlled world-wide by widespread immunization. The major cause of the decline in the morbidity and mortality of the disease is the intensive World Health Organization's Expanded Program on Immunization.
openaire +1 more source
[Acellular anti-pertussis vaccine].
Bulletin de la Societe de pathologie exotique (1990), 1992Since several years, pertussis has increased especially in non-immunized young infants under 6 months of age, in countries where pertussis-immunization is in widespread use. The whole-cellular pertussis vaccine so far used in these countries is not well tolerated, has been indicted in adverse neurological complications, and offers significant but ...
P, Bégué, E, Grimpel, S, Baron
openaire +1 more source